GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atomo Diagnostics Ltd (ASX:AT1) » Definitions » Net Income From Continuing Operations

Atomo Diagnostics (ASX:AT1) Net Income From Continuing Operations : A$-6.46 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Atomo Diagnostics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Atomo Diagnostics's net income from continuing operations for the six months ended in Dec. 2024 was A$-2.76 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was A$-6.46 Mil.

Atomo Diagnostics Net Income From Continuing Operations Historical Data

The historical data trend for Atomo Diagnostics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atomo Diagnostics Net Income From Continuing Operations Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
Net Income From Continuing Operations
-9.22 -6.02 -5.71 -9.96 -6.85

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -5.74 -4.21 -3.15 -3.70 -2.76

Atomo Diagnostics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-6.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atomo Diagnostics Ltd (ASX:AT1) » Definitions » Net Income From Continuing Operations
Comparable Companies
ASX:UBI ASX:HMD ASX:CBL ASX:OSL ASX:IRX ASX:ADRDA ASX:UCM ASX:CDX ASX:LDX ASX:NTI ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM STE PODD
Traded in Other Exchanges
N/A
Address
3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Website
https://www.atomodiagnostics.com
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.

Atomo Diagnostics Headlines

No Headlines